All News

A developing advocacy campaign in Washington state has the AACU Government Affairs team implementing the very practices described in this space and thereby urged upon urologists in seemingly ad nauseum Calls to Action.

Avanafil, an investigational phosphodiesterase type-5 inhibitor, appears to significantly improve erectile function with low rates of side effects, according to results from a randomized, placebo-controlled, phase III study.

Prostate cancer patients tend to opt for a major cancer center if they have severe disease, but stay closer to home for less complicated cases, even when offered a model of care that taps numerous experts, according to a study by researchers from Duke Cancer Institute, Durham, NC.

New Jersey Governor Chris Christie has signed legislation opposing an October 2011 U.S. Preventive Services Task Force (USPSTF) draft recommendation that healthy men should no longer receive PSA tests as part of routine cancer screening.

The AUA recently honored Brigadier General (U.S. Army ret.) C. William Fox, Jr, MD, with honorary membership for outstanding service to his country and his profession.

Veterans Affairs hospitals screen elderly men with limited life expectancies for prostate cancer at surprisingly high rates, even though guidelines recommend against such screening, according to a recent study.

Results from testing in an initial patient cohort indicate the potential for a six-gene, whole blood RNA-based expression panel to predict survival in men with progressive metastatic castration-resistant prostate cancer.

Pain interference with daily functioning was significantly less in men with castrate-resistant prostate cancer who were treated with the RANK ligand inhibitor denosumab (XGEVA) compared to zoledronic acid (Zometa) as part of a multinational, double-blind, randomized trial.

Although percutaneous nephrolithotomy (PCNL) comprises only 4% to 6% of all stone surgeries, it behooves the urologist with an interest in stone disease to be facile in this treatment modality in order to offer patients the most appropriate and effective treatment for their stones.

Results of in vitro studies indicate that E-twenty six (ETS) gene fusions in prostate cancer may be a biomarker of radiation resistance and a potential target for reversing radioresistance through treatment with a poly(ADP-ribose)polymerase 1 (PARP1) inhibitor.